Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 134 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Any Condition Clear all

Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 12
States / cities: Duarte, California • Santa Rosa, California • Chicago, Illinois + 8 more

Conditions: Rheumatoid Arthritis
Interventions: INCB028050, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more

Conditions: Dehydration
Interventions: Hoist Group; Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 4 Years to 98 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Any Ear Nose or Throat Conditions, With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Interventions: Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution; Drug
Lead sponsor: Lannett Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3, High-risk HPV (Any Strain)
Interventions: Artesunate Suppositories; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Towson, Maryland

Conditions: Melanoma
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Interventions: Doxil, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Pegfilgrastim; Drug
Lead sponsor: The Alvin and Lois Lapidus Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Baltimore, Maryland • Randallstown, Maryland

Conditions: Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions: Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Any Cancer Diagnosis
Interventions: Play Intervention, Questionnaires; Behavioral · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 4 Years to 10 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreatic Cancer, ATM, BRCA, Hereditary Cancer
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Any Conditions That Are Genetic or Suspected to be Genetic in Origin
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2050
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Phoenix, Arizona • Las Vegas, Nevada

Conditions: Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
Interventions: TriVerity; Diagnostic Test
Lead sponsor: Inflammatix; Industry
Eligibility: 18 Years and older
Enrollment: 1,441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • Los Angeles, California • Sacramento, California + 22 more

Conditions: Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Mesothelioma, Esophageal Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, Salivary Gland Carcinomas, Head and Neck Cancers - Salivary Gland, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Throat, Small Cell Lung Cancer ( SCLC ), Lung Cancer (Locally Advanced or Metastatic), Head and Neck Cancers - Tonsils, Head and Neck Cancers Hypopharynx, Head and Neck Cancers Larynx, Head and Neck Cancers Lip, Head and Neck Cancers Nasopharynx, Head and Neck Cancers Oral Cavity, Head and Neck Cancers, Head and Neck Cancers Oropharynx, Head and Neck Cancers Trachea
Interventions: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg); Drug
Lead sponsor: VM Oncology, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 12
States / cities: Santa Rosa, California • Hartford, Connecticut • Washington D.C., District of Columbia + 9 more

Conditions: Not Seeking to Treat Any Conditions
Interventions: Mindfulness training, Tracking time spent on mobile device; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Any Solid Tumor or Lymphoma
Interventions: OSI-027; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cancer in Remission (Any Type or Stage), Depression, Anxiety
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Northwestern University; Other
Eligibility: 22 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Cancer, Adenocarcinoma
Interventions: sunitinib; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diarrhea
Interventions: Enterade beverage; Dietary Supplement
Lead sponsor: GenesisCare USA; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer
Interventions: Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Plantation, Florida • Norfolk, Virginia

Conditions: Skin Cancer
Interventions: Scalpel for tissue scoring, Surgical marker for tissue marking; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Urea Cycle Disorders, Inborn
Interventions: No Intervention; Other
Lead sponsor: iECURE, Inc.; Industry
Eligibility: 7 Months to 15 Months
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Any Single Gene Disorder (Cystic Fibrosis, Tay-Sachs)
Interventions: preimplantation diagnosis; Other
Lead sponsor: Natera, Inc.; Industry
Eligibility: Up to 40 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Metastatic Renal Cell Cancer
Interventions: Everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
U.S. locations: 15
States / cities: Springdale, Arkansas • Aurora, Colorado • Ocoee, Florida + 12 more

Search by objective public record fields.

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Measuring Pain and Hydration After Tonsillectomy

Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Tandem Auto-Allo Transplant for Lymphoma

A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer

Pancreatic Cancer Registry: For Any Person With a Personal or Family History

UCSF Center for Genome Surgery Biobank and Registry

A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Stress-physiology Coherence, Interoception, and Well-being Following Mindfulness Training or Tracking Time Spent on Mobile Device

Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety

Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks

Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)

Concurrent Single Gene and 24 Chromosome Aneuploidy Preimplantation Genetic Diagnosis (PGD)

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy